"...RESULTS: Twenty-five patients with a median Eastern Cooperative Oncology Group performance status of 0 were accrued. There were no grade III or IV adverse events definitely related to the antibody. There were three episodes of tumor-related bleeding. Infusions of rhuMAb VEGF were well tolerated without significant toxicity. Grades I and II adverse events possibly or probably related to study drug included asthenia, headache, and nausea. Pharmacokinetics revealed a linear profile with a half-life of 21 days. There were no objective responses, though 12 patients experienced stable disease over the duration of the study...."
"...Efficacy No patient treated on this phase I study experienced an objective partial or complete response. One patient with renal cell carcinoma, treated at the 10 mg/kg dose level, experienced a minor response with an approximately 20% to 30% reduction in the sum of perpendicular diameters of pulmonary and lymph node metastases. Among 23 patients who were assessable for response at 70 days, 12 experienced stable disease over the 70-day study interval, with the remaining 11 patients demonstrating progressive disease...."
Market Data 
Markets 
AI
